Sign inJoin waitlistJoin the waitlist

Karen Reckamp

Co-Director and Associate Professor of Medicine · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · ·

History

Medicine · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

University of California-Los Angeles
2001–2003
Internal Medicine
Barnes-Jewish Hospital
1998–2001
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1994–1998

Research

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,024 citations
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 1,060 citations
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate…
Journal of Clinical Oncology · 2017 · 731 citations

MK
Marianna Koczywas
26 papers
Steven Dubinett
26 papers
Jyoti Patel
21 papers
Robert Figlin
21 papers
LH
Leora Horn
18 papers
Ross Camidge
18 papers
RS
Ravi Salgia
17 papers
Ramaswamy Govindan
16 papers
Wallace Akerley
15 papers
DE
David Ettinger
14 papers
GO
Gregory Otterson
14 papers
GR
Gregory Riely
14 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $4.6K · University of Southern California
2008–2009
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $239.7K · Beckman Research Institute/City of Hope

Clinical trials

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 1
Karen Reckamp, MD, MS
2023–2029
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Principal investigator · Active not recruiting · Phase 3
SWOG Cancer Research Network
2023–2028
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2019–2024
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Principal investigator · Terminated · Phase 1
ACEA Therapeutics, Inc.
2015–2019